Podcasts about healthtech

Sarah Russell picked up a phrase at her new job at Anthropic: a "non-regrettable primitive." It's how she describes the kind of infrastructure she thinks Anthropic should be building in healthcare, and it says a lot about how one of the most closely watched companies in health AI is positioning itself. In this episode, Steve talks with Sarah Russell, MD healthcare and life sciences lead at Anthropic. This conversation comes as Anthropic heads toward what's shaping up to be one of the most anticipated IPOs in years.We cover:What Anthropic is doing in healthcareWhy HIPAA is struggling to keep up with AI agents Where she thinks AI will change care first (it's not where you'd expect!)The two very different bars regulators are weighing AI against, and why the choice matters more than most people realizeThe one piece of advice from her father that still shapes how she builds teams, and what she tells doctors nervous about a career in medicine nowAbout our guest:Sarah currently works on healthcare and life sciences projects at Anthropic. She is particularly passionate about research that explores how to make Claude safer and less confidently wrong. Prior to Anthropic, she was at Google X, an innovation hub at Alphabet, where she learned to lead teams of smart engineers building ML- and LLM-based products. Seeing the earliest version of Google's Med-PaLM summarize a patient chart made her excited about healthcare technology all over again. Prior to Google, she was a CMIO in the VA system and a start-up founder. A graduate of Harvard College and Harvard Medical School, Sarah did her internal medicine residency at MGH and completed an MBA at Wharton. She still practices part-time in Urgent Care at Stanford, where she is an Assistant Professor.⸺

Wie können etablierte Unternehmen und innovative Start-ups voneinander profitieren? Und welche Technologien werden Wirtschaft und Arbeitswelt in den kommenden Jahren verändern?Diesen Fragen widmet sich unsere Podcast-Folge 205 rund um das Future Tech Fest 2026 im AREAL BÖHLER in Düsseldorf.Rund 300 nationale und internationale Tech-Start-ups präsentierten ihre Ideen, Produkte und Lösungen. Von Künstlicher Intelligenz und HealthTech über Bildung und digitale Geschäftsmodelle bis hin zu neuen Technologien für Unternehmen: Die Expo machte Zukunft nicht nur sichtbar, sondern erlebbar.Wir haben mit einigen Teilnehmerinnen und Teilnehmern gesprochen und uns angeschaut, welche Innovationen besonders interessant sind – und vor allem, welche Chancen sich daraus für etablierte Unternehmen ergeben.Denn beim Future Tech Fest geht es um mehr als um neue Technologien. Es geht um Menschen und Kontakte. Unternehmen können direkt mit Gründerinnen und Gründern ins Gespräch kommen, Ideen austauschen und mögliche Kooperationen ausloten.Kontakte statt Visitenkarten sammelnGenau diesen Austausch förderte auch die exklusive Führung der Unternehmerschaft Düsseldorf. Mitglieder konnten gemeinsam mit der Wirtschaftsförderung der Landeshauptstadt Düsseldorf das Festivalgelände erkunden, ausgewählte Start-ups kennenlernen und direkt mit den Menschen hinter den Innovationen ins Gespräch kommen.Denn manchmal entsteht eine neue Geschäftsidee nicht am Schreibtisch – sondern im Gespräch mit jemandem, den man vorher noch nicht kannte.Neben der großen Expo bot das Future Tech Fest ein umfangreiches Bühnen- und Workshopprogramm. Auf der Main Stage standen unter anderem Künstliche Intelligenz, Gesundheit und Unternehmertum im Mittelpunkt. Auf der Startup Stage präsentierten junge Unternehmen ihre Geschäftsmodelle in Pitch-Runden. Beim B2B-Speed-Dating und weiteren Networking-Formaten ging es ganz konkret darum, neue Geschäftskontakte zu schaffen.Was bleibt von einem solchen Tag? Neue Ideen, neue Perspektiven und vielleicht der eine oder andere Kontakt, aus dem später tatsächlich ein gemeinsames Projekt wird.In Podcast-Folge 205 nehmen wir Sie mit zum Future Tech Fest 2026 und sprechen darüber, was Unternehmen von der Start-up-Szene lernen können – und warum Innovation vor allem dann interessant wird, wenn aus einer guten Idee eine konkrete Verbindung entsteht.

On this episode of the Medical Alley Podcast, we sit down with Paula Norbom, founder and CEO of Talencio, to unpack what's happening in today's health and life sciences job market and how professionals can position themselves for what comes next. Paula shares practical advice for approaching your career as a "company of one," defining the value you bring, strengthening your LinkedIn presence, networking more effectively, and using AI as a tool in your job search. She also explains why hiring timelines have stretched, and what job seekers can do to stay focused when a search takes longer than expected. Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram. 

The 1 word that is your best bet in getting a response from your doctor when using a patient portal to ask questions. See omnystudio.com/listener for privacy information.

Healthcare costs are taking an ever-larger bite out of American workers' compensation. This Labor Day, we're revisiting a conversation with Health Rosetta CEO Dave Chase about why healthcare has become so expensive and what employers can do about it.Dave argues that healthcare itself isn't the problem: clinicians receive only a fraction of every dollar spent, while price gouging, administrative bloat, and middlemen consume much of the rest. He explains how community-owned health plans are rebuilding employer healthcare around primary care, transparency, and better incentives—and how the savings can flow back to workers and their communities.We cover:Why rising healthcare costs ultimately come out of workers' payHow community-owned health plans cut out costly middlemenWhy better primary care can lower costs while improving outcomesHow employers can rebuild health benefits from the ground upWhy Dave believes open-source healthcare could challenge entrenched incumbents ⸺

Propensity Modeling: How to Find Your Most Valuable Leads Does your team keep chasing more leads but can't explain why the pipeline doesn't turn into revenue? This episode is for you. On this episode host Adam Turinas speaks with Aaron Burnett, founder and CEO of Wheelhouse DMG, who built his agency specifically for privacy-first industries like healthcare and medtech, and he walked Adam through something most agencies can't do: predicting the dollar value of a lead in real time, without ever touching protected health information.

Health insurance is one of the few products people pay for while hoping they never have to use it. Alan is trying to change that.In this episode, Jean-Charles Samuelian, Co-founder and CEO of Alan, shares how the company built a full-stack health insurance platform designed around prevention, personalization, and everyday engagement rather than simply paying claims when something goes wrong.They discuss why Alan chose to become a regulated insurer instead of a broker or technology provider, how owning the entire insurance stack changed the customer experience and economics, and why the company believes prevention can become central to the future of health insurance.Jean-Charles also explains how Alan is using AI across customer service, operations, and healthcare through its AI companion Mo, why personalization should improve care rather than determine who can afford insurance, and how the company is building one technology platform across France, Spain, Belgium, and Canada.

It's our monthly Digital Health Download, and September's stories all circle the same tension: technology keeps promising to fix healthcare's problems, but just as often it moves them somewhere else, or creates new ones entirely. This week, Halle unpacks a news-heavy month, weighing who actually benefits as markets, algorithms, and AI get closer to our health decisions.We cover:Americans can now bet on clinical trials and FDA regulatory reviews - but do we want that?Meta's massive settlement over harming childrenThe surprising reason AI might be making healthcare more expensive instead of lessA new study on the biggest lever we're not pulling to bend the healthcare cost curveTwo lawsuits rattling a popular wearable and a celebrity-backed mental health startupWhat a widely used drug class reveals about bias in hiring, and the uncomfortable questions that raises⸺

In this episode of Medsider Radio, we sat down with Deanna Harshbarger, CEO of Cala Health.Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor.Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care.In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Deanna Harshbarger, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:34) - Deanna's journey from J&J, Boston Scientific, and Medtronic to Cala Health (08:16) - How Cala personalized therapy around each patient's unique experience (11:53) - Operating lessons Deanna carried from strategics to startups (22:27) - The unboxing interview that changed Cala's product design (29:16) - How Cala balanced feasibility studies, RCTs, and real-world evidence after its commercial launch (34:33) - Years of clinical evidence helped Cala win reimbursement for a new therapy (38:52) - The case for holding back when you're ready to commercialize (44:30) - Why fundraising is both a sprint and a marathon

Why Social Selling Beats Cold Outreach and What Actually Works Now On this episode host Adam Turinas closes out the four-part series on AI and sales enablement, and sits down with Tim Hughes, co-founder of DLA Ignite and one of the most respected voices in social selling. If you have felt like the channels you used to count on for pipeline just are not producing the way they used to, you're not alone. Cold call connection rates have dropped to around 3 percent, email is getting buried by spam filters, and now LinkedIn is starting to go the same way as more salespeople lean on AI to fire off generic connect-and-pitch sequences that buyers can spot from a mile away. Tim built the only certified social selling methodology in the world, just released the fourth edition of his book Social Selling and Influence, and spent the last year building an AI platform, Azpertilo.ai, that helps salespeople sound more like themselves, not less. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode, Cathy and Lee discuss the latest developments in tech, including Meta's settlement, new Apple hardware, AI market potential, and health tech innovations like regrowing teeth. They explore the implications of these advancements and what they mean for the future of technology and society.keywords: tech news, Meta settlement, Apple hardware, AI market, health tech, regrowing teeth, AI bubble, Linux, AI investmentskey topicsMeta's settlement and its implications for social media and privacyNew Apple hardware releases and their market impactThe potential revenue and market share of AI companies like AnthropicInnovations in health tech, including regrowing teeth and robot-assisted blood drawsThe sustainability of the AI market bubble and investment risksThe significance of Linux's 35-year history in modern technologyThe influence of AI on employment, economy, and societyThe race of AI companies towards IPO and market dominancetakeawaysMeta's settlement of 17 billion dollars is significant but not crippling for the company.Apple's recent hardware releases show a trend towards high prices and powerful specs, especially in the Mac Mini line.AI companies like Anthropic project enormous potential revenues, but market share assumptions are overly optimistic.Health tech innovations such as regrowing teeth could revolutionize dentistry and reduce costs.The AI market bubble may be unsustainable, with many companies overestimating their market share and revenue.Linux's 35-year history demonstrates its foundational role in modern computing and the internet.Investors should be cautious about AI IPOs, as the projected market sizes are often unrealistic.Sound Bites"Seventeen billion dollars is a lot of money, but not for Meta.""Apple's new Mac Minis are tiny but expensive.""Regrowing teeth could change dentistry forever."Chapters00:00Introduction and Cathy back on the road01:36Meta Settles for 17 Billion Dollars03:37Apple's Hardware Launches and Price Drops07:37Apple's Polishing Cloth Price Drop09:19Google Pixel Eleven Pro Review11:12Global Listeners and Appreciation11:44Robot Drawing Blood and Medical Tech16:27Regrowing Teeth: The Future of Dentistry20:07AI Market Potential and Investment Risks28:02Linux Turns 35: Its Impact and Future

Send us Fan MailMost health tech companies do not fail because their product does not work. They fail because they never defined what success looked like before the pilot ended and the budget conversation began.Dan Galles, Partner at Allumia Ventures, joins host David E. Williams to discuss what 16 exits over a decade investing from inside Providence Health System revealed about what it actually takes to go from pilot to enterprise contract, and why the care model transformation AI is enabling may be the most important investment theme in healthcare right now.

In this episode of Medsider Radio, we sat down with Michael Mangano, President and CEO of ABK Biomedical. ABK's Eye90 is an investigational Y90 radioembolization device for treating unresectable liver cancer.Michael brings over 30 years of medical device experience, including 15 years at Boston Scientific in commercial and international leadership roles. He previously served as CEO of ReShape Medical and as President of the Americas for Sirtex Medical, scaling regional revenues from $34 million to over $130 million.In this interview, Michael discusses the thinking behind ABK's pivot into Y-90 radioembolization, what it takes to execute a 120-patient pivotal trial while retaining ownership over the clinical function, how to build capabilities that competitors can't quickly catch up to, and why the player-coach culture gives startups an execution advantage.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Michael Mangano, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:09) - Michael's journey from Boston Scientific and Sirtex to leading ABK Biomedical (04:54) - Why Michael pivoted ABK from embolization to radioembolization as soon as he joined as CEO (09:24) - How ABK reimagined Y-90 around physician control and patient-specific dosing (21:08) - What a functioning player-coach culture looks like inside a startup (27:26) - Lessons learned from a complex 120-person pivotal trial and how ABK remained the face of the study while partnering with a CRO (37:13) - How ABK is building advantages competitors can't easily replicate (42:50) - Michael's framework for choosing the right investors

We don't talk enough about how hard it actually is to build a healthcare startup. Behind SmarterDx's story, now one of the biggest health AI exits to date, were 18 months without a single customer, a pivot that seemed to make no product sense, and two co-founders who went back to working as hospitalists just to get by.In this episode, Steve gets the real story from Dr. Michael Gao and Dr. Joshua Geleris about the challenges they faced and what ultimately unlocked real growth and led to their billion+ acquisition by New Mountain Capital.We cover:Why their first product idea failed and what customer objections actually taught them to build insteadThe counterintuitive workflow that made contingency pricing possibleHow AI translation of clinical notes into billing codes now outperforms the average human, and what that means for coders and nursesWhy "moat" is the wrong metaphor and what a flywheel looks like insteadWhat they'd do differently in the acquisition processAbout our guests:Michael Gao, MD, the CEO and co-founder of SmarterDx. Prior to founding SmarterDx, Dr. Gao was the Medical Director for Transformation at NewYork-Presbyterian, where he led applied AI development, implementation, and strategy for the health system. Dr. Gao holds faculty positions at the Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine. Dr. Gao completed his internship and residency in Internal Medicine at NewYork-Presbyterian.. He received his M.D. from the University of Michigan and a B.S from the University of California Los Angeles.Josh Geleris, MD, is the Head of Product and co-founder of SmarterDx. Prior to SmarterDx, he was Assistant Professor of Medicine at Columbia University, where he was funded by the National Institutes of Health and the Department of Defense for clinical informatics and data science, and led implementation of Epic for providers. Dr. Geleris completed his MD at the Technion-Israeli Institute of Technology and his Internal Medicine internship and residency at NewYork-Presbyterian. ⸺

Jaarlijks krijgen in Nederland 3.200 mensen de diagnose hoofd-halskanker. Voor veel van hen is opereren de belangrijkste behandeling, met blijvende gevolgen voor spreken, slikken, eten en uiterlijk. Bestralen kan bovendien maar één keer op dezelfde plek, terwijl juist deze patiëntengroep vaak een tweede of derde tumor krijgt. In Utrecht werken onderzoekers daarom aan een medicijn dat de tumor zelf opzoekt en pas actief wordt als de arts er licht op schijnt. In deze aflevering van BNR Beter bespreekt Nina van den Dungen de ontwikkeling van fotodynamische therapie met nanobodies. Te gast zijn Remco de Bree, hoogleraar Hoofd-Hals Chirurgische Oncologie en afdelingshoofd bij het UMC Utrecht, en Sebas Pronk, CEO en medeoprichter van biotechbedrijf Lumox. De Bree legt uit waarom het hoofd-halsgebied zo lastig te behandelen is. Vitale functies liggen dicht op elkaar, chirurgen moeten een veiligheidsmarge aanhouden rond zenuwen en de halsslagader. Hij verwacht dat lichttherapie geen bestaande behandeling overbodig maakt, maar een extra pijler wordt in het arsenaal, in eerste instantie voor grote, oppervlakkige tumoren die van buitenaf belicht kunnen worden. Pronk beschrijft hoe Lumox twee bestaande technieken combineert. Een nanobody, een mini-antilichaam dat tien keer kleiner is dan een gewoon antilichaam en oorspronkelijk uit lamabloed komt, brengt een lichtgevoelig medicijn naar de tumorcel. Rood licht activeert het middel alleen daar. Omdat het nanobody snel weer uit het lichaam verdwijnt, hoeft een patiënt ongeveer een uur voor en twee tot vier uur na de behandeling uit het licht te blijven, in plaats van dagen. De therapie is getest in muizen en bij kattenpatiënten. Het onderliggende onderzoek loopt al ruim tien jaar in de groep van Sabrina Oliveira aan de Universiteit Utrecht. Verder gaat het over de financiering en de stap naar de kliniek. KWF Kankerbestrijding investeert ruim 4,5 miljoen euro in de eerste patiëntenstudie, maar Lumox heeft in totaal ongeveer 20 miljoen euro nodig tot en met fase 1. Pronk zoekt aanvullend geld bij investeerders en moet de productie opschalen van milligrammen naar tientallen grammen. Een fase 3-studie kost honderden miljoenen, waarvoor een farmaceut nodig. Ook komt de overstap van onderzoeker naar ondernemer aan bod, en de vraag hoe het Utrechtse medicijn zich verhoudt tot een Japanse concurrent die met gewone antilichamen werkt. Over de vraag waarom nieuwe kankermedicijnen in Nederland zo laat bij patiënten belanden, is deze eerdere aflevering van BNR Beter terug te luisteren. Over deze podcast BNR Beter is het wekelijkse programma van BNR Nieuwsradio over een toekomstbestendige zorgsector. Elke week bespreekt presentator Nina van den Dungen met zorgprofessionals, ondernemers en beleidsmakers hoe de Nederlandse zorg met technologie, innovatie, regelgeving en wetenschap beter kan worden. BNR Beter is elke maandag om 15:30 op de radio te beluisteren bij BNR Nieuwsradio, en vanaf dat moment ook als podcast via deze feed. Over de makers Nina van den Dungen (1987) is freelance journalist en als radio- en podcastpresentator al ruim 15 jaar verbonden aan BNR. Zo is ze regelmatig te horen als presentator van de nieuwsprogramma's in de ochtend- en avondspits en daarnaast presenteert ze wekelijks de beleggingspodcast Doorgelicht en BNR Beter over de zorgsector. Stijn Goossens (1996) is de redacteur van BNR Beter en plaatsvervangend presentator. Bij BNR houdt Stijn zich bezig met onderwerpen over tech, wetenschap en innovatie. Hij presenteerde de podcast Op de zaak en test elke vrijdag een nieuw techproduct in de Ochtendspits op BNR. Hiervoor was Stijn werkzaam voor NTR Wetenschap en techplatform Bright.See omnystudio.com/listener for privacy information.

Building an AI Lead Scoring System That Boosted Conversion by 70% Your marketing engine is generating leads, but how do you know which ones are actually worth handing to sales? That is the question at the heart of this episode, and it is one that gets harder to answer the bigger your funnel gets. On this episode, host Adam Turinas sits down with Nick Panayi, a technology marketing veteran who most recently led marketing at Inovalon. If you listened to the episode with Nick last year, you know he has spent his career at the intersection of marketing and AI. This time he is back to walk Adam through something he built with his partner Chris Marin: an AI-powered lead scoring system that moved his team's MQL-to-opportunity conversion rate from 10 percent to 17 percent in a single quarter. That is a 70 percent improvement in lead conversion. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

This week on Pulse: Amplify, Louise and George speak with EMR pioneer Dr NT Cheung.Dr NT Cheung joined the Hong Kong Hospital Authority when clinical computing was virtually non-existent, and went on to help build one of the world's largest integrated, longitudinal electronic patient record systems.NT reflects on Hong Kong's remarkable 30-year digital health journey, why building its technology in-house proved so valuable, and what other health systems can learn from its clinician-led, incremental approach. They explore the extraordinary opportunity created by three decades of consistently collected patient data, cross-border record sharing with mainland China, and technology's role in supporting an ageing society.NT also offers a timely warning for the AI era: healthcare is too complex to be transformed by technology alone. AI may be extraordinarily powerful, but it remains a tool, and the goal must be to make every interaction between patients, clinicians and the health system a little smoother and better.Connect with NT on LinkedInVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

In this episode of Medsider Radio, we sat down with we sat down with Murthy Simhambhatla, CEO of SetPoint Medical.SetPoint is commercializing the first FDA-approved neuroimmune modulation implant for rheumatoid arthritis.Previously, Murthy was CEO of Evolus, leading the company through its IPO, and held multiple leadership roles at Abbott, including President of Abbott Medical Optics and head of the company's Ibis Biosciences molecular diagnostics business. Earlier in his career, Murthy led development of Abbott's XIENCE drug-eluting stent platform following Abbott's acquisition of Guidant. Murthy holds a Ph.D. in Polymer Engineering and is a Fellow of the American Institute for Medical and Biological Engineering.In this interview, Murthy discusses building commercial conviction years before launch, how to sequence platform indications around adjacent markets, and why SetPoint built its reimbursement function in-house rather than outsourcing it.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Murthy Simhambhatla, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:18) - Murthy's journey from Guidant, Abbott, and Evolus to leading SetPoint Medical (09:53) - How SetPoint stimulates the vagus nerve to reprogram the immune system (11:32) - Why SetPoint built a reimbursement hub around the entire referral workflow (21:36) - A guide to building technical and commercial conviction for a novel therapy (26:58) - The trifecta Murthy wanted in place before commercial launch (30:56) - Why rheumatoid arthritis became SetPoint's first indication (36:11) - How commercial adjacency shapes platform expansion (42:20) - A business case for handholding patients through reimbursement (48:03) - The two lessons behind every skeptical investor question

It's back-to-school szn, and while some kids are stressing over earlier wake-ups, this year's incoming medical students have a bigger question to answer: how do you train for a career that could still have you practicing medicine in the 2070s, when the tools of medicine are changing so rapidly?For our back-to-school episode, we sat down with Stanford University School of Medicine Dean Dr. Lloyd Minor to talk about how AI is already reshaping what future doctors learn and how they're taught, as well as what's still not working in American healthcare.We cover:What medical students are actually being taught about AI, and where Stanford still draws the lineWhy Stanford's tumor boards no longer start with humansThe surprising way Dr. Minor thinks AI could level the playing field in healthcare accessWhy the same AI tools helping patients feel more informed are also making them more anxiousThe counterintuitive reason new medical technology gets more expensive before it gets cheaperWhat's still standing in the way of a vision for precision medicine that's been decades in the makingAbout our guest:Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University. Dr. Minor also is a professor of Otolaryngology–Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.As dean, Dr. Minor has had an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Medicine Children's Health. With his leadership, Stanford Medicine leads the biomedical revolution in Precision Health. His book, “Discovering Precision Health,” describes this shift to more preventive, personalized health care and highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases. In 2021, Dr. Minor articulated and began realizing a bold vision to transform the future of life sciences at Stanford University and beyond – a multi-decade journey enabled by Precision Health.In August 2023, Dr. Minor was appointed Vice President for Medical Affairs to lead all matters related to health and medicine at Stanford University.Before Stanford, Dr. Minor was provost and senior vice president for academic affairs of Johns Hopkins University. Prior to this appointment in 2009, Dr. Minor served as the Andelot Professor and director (chair) of the Department of Otolaryngology–Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital.With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders perhaps best known for discovering superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.In 2012, Dr. Minor was elected to the National Academy of Medicine.—

Dans cet épisode de Cheminements, Marguerite de Rodellec reçoit Laurence Comte-Arassus, ancienne présidente de Medtronic France et GE HealthCare France, présidente du SNITEM et chevalière de la Légion d'honneur. Ensemble, elles abordent un sujet encore trop souvent fragmenté : la conciliation entre une très haute carrière de dirigeante dans la HealthTech et la maternité. Un échange puissant qui déconstruit les injonctions, prône l'écoute de soi et rappelle que diriger tout comme transmettre relèvent d'une même vocation : prendre soin des autres.Au programme de cet épisode :La naissance d'une vocation dans le dispositif médical : du désir de soigner sur le terrain au pilotage de grands groupes.L'expérience d'être la première femme à la tête de Medtronic France et les défis du leadership féminin.La maternité en parallèle d'une carrière intense : briser la peur de ne pas être une "bonne mère" et s'organiser sans culpabilité.La gestion des épreuves personnelles, de la maladie d'un enfant aux urgences professionnelles.Le mentorat et la sororité : la responsabilité d'aider les femmes à rester elles-mêmes sans chercher à copier les hommes.L'importance fondamentale de prendre soin de soi pour pouvoir durablement prendre soin des autres.Dans Cheminements, des femmes du quotidien, vos voisines, vos collègues, vos sœurs, partagent leurs parcours de santé mentale, physique ou sociale, entre luttes, victoires et transformations, pour mettre en lumière des sujets trop souvent passés sous silence.

Send us Fan MailWelcome back, everyone! In this episode, I'm diving deep into a topic that has been on every writer's mind lately: Artificial Intelligence. As a nurse with over 20 years of experience and a decade in the freelance health writing world, I've seen first-hand how AI is shifting the landscape. While it's certainly disrupted the industry, I want to share why I believe this is actually an incredible time for clinicians to pivot into writing.Key TakeawaysThe “Bottom” of the Market is Gone (and that's okay): AI has effectively taken over the low-paying, generic, high-volume “content treadmill.” While this has disrupted the market, it's not a loss for us. That type of work prioritized quantity over quality, and its decline opens up more space for meaningful, expert-driven content.Human Clinicians are Indispensable: AI lacks the ability to grasp the “gray areas” of medicine. It cannot replicate the clinical nuance, deep empathy, or the ability to interpret complex patient needs that a healthcare professional provides. Our expertise ensures clinical accuracy and a human tone that AI simply can't match.Growing Opportunities: Demand is actually increasing for clinicians in several key areas:Patient Education: Refining AI drafts to ensure they are empathetic and easy for patients to understand.Health Tech & Startups: Bridging the gap between technical engineering and medical accuracy.Ghostwriting: Helping healthcare leaders maintain their professional voice and authority.Continuing Education: Creating specialized professional development materials for other nurses.Actionable Steps1. Pick a Niche Based on Internalized Expertise: Identify a clinical area you know so well you could talk about it in your sleep. This “internalized” knowledge is your competitive advantage over AI.2. Define Your Positioning: Create a clear statement for your LinkedIn and pitches using this formula: “I help [target audience] with [specific service] so they can [desired result].”Thank you for tuning in! Remember, your clinical voice is more valuable now than ever. Keep writing, stay savvy, and I'll catch you in the next episode.Welcome to the Savvy Scribe Podcast, I'm so glad you're here! Before we start the show, if you're interested, we have a free Facebook group called "Savvy Nurse Writer Community"I appreciate you following me and listening today. I would LOVE for you to subscribe: ITUNESAnd if you love it, can I ask for a

Finding Your True Customer Profile with Bruce Brandes In this episode, host Adam Turinas sits down with Bruce Brandes, a 35-year healthtech veteran. Together with his longtime friend and business partner Brian Shulman, he is building WhaleHawk, which they call the first agentic sales accelerator built specifically for healthcare. We dig into why go-to-market in healthcare is so uniquely hard, why generic prompting in Claude or ChatGPT will not solve it, and what it actually takes to combine AI with deep healthcare-specific data to find the right accounts, at the right time, with a warm path in. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Send us Fan MailFear paralyzed him on Bitcoin. A decade in prestigious law firms surrounded by smart, unhappy people showed him what success without purpose looks like. And a stranger in Home Depot delivered a message that changed the direction of his business. Otis Grigsby played 6 years in the NFL, practiced law at large firms for 6 years, and is now part-legal, part-growth, part-strategy at his wife's health tech marketing agency - and watching ChatGPT recommend their services to strangers without any programming on their end.In this episode, Otis delivers one of the most honest 10 minutes on this stage: fear is an absolute killer, it paralyzes your training, it makes you forget everything you've built - and it shows up daily whether you have a two-year-old at home or a nine-figure deal on the table. He talks about missing the Bitcoin run, what Christmas in big law looks like when IBM needs a deal closed, and the four-month delay before he finally followed the advice that unlocked his business. Family Office Club has hosted 300+ events over 19 years and $1 billion+ in community transactions - Otis is the kind of operator you only meet in rooms like this.What is the one thing in your business you keep holding onto that you know you need to let go of? About Family Office ClubThe world's largest investor club in the family office space. 19 years. 300+ events. 16 million members. $1B+ in community transactions.

Sharon Wood, founder and CEO of Happy People Games and creator of The New Forevers, a memory wellness company helping older adults, families, and caregivers reconnect through music, photos, and meaningful play.Through her two apps, Timeless Tunes and Still Frames, Sharon uses reminiscence therapy to stimulate memory, lift mood, and strengthen intergenerational connection for adults over 50, including those experiencing Alzheimer's, dementia, or mild cognitive impairment.Now, Sharon's journey from nearly four decades in gaming, including launching one of the most successful games, Grand Theft Auto, to building a new category in memory wellness shows how technology can be used for something deeply human.And while growing awareness for a space many families only discover once they are directly affected, she is helping people feel more connected, supported, and seen through the power of play.Here's where to find more:https://thenewforevers.com/ https://www.facebook.com/thenewforevers https://www.instagram.com/thenewforevers________________________________________________Welcome to The Unforget Yourself Show where we use the power of woo and the proof of science to help you identify your blind spots, and get over your own bullshit so that you can do the fucking thing you ACTUALLY want to do!We're Mark and Katie, the founders of Unforget Yourself and the creators of the Unforget Yourself System and on this podcast, we're here to share REAL conversations about what goes on inside the heart and minds of those brave and crazy enough to start their own business. From the accidental entrepreneur to the laser-focused CEO, we find out how they got to where they are today, not by hearing the go-to story of their success, but talking about how we all have our own BS to deal with and it's through facing ourselves that we find a way to do the fucking thing.Along the way, we hope to show you that YOU are the most important asset in your business (and your life - duh!). Being a business owner is tough! With vulnerability and humor, we get to the real story behind their success and show you that you're not alone._____________________Find all our links to all the things like the socials, how to work with us and how to apply to be on the podcast here:https://linktr.ee/unforgetyourself

This week on Pulse: Hot Topics, Louise and George explore the rapidly shifting boundaries of science, AI and human health.They unpack the extraordinary research using AI to design entirely new, functioning viruses, and the biosecurity questions that follow. Then, turning the discussion to South Australia's newly announced Royal Commission into AI and whether governance can possibly keep pace with technological change.Then they look at the emerging era of the “continuous human”: Germany's €40 million push to crack continuous hormone monitoring, and Google's enormous SensorFM foundation model, trained on more than a trillion minutes of wearable data, which could point towards a future of personalised, continuous health intelligence.Plus, George recommends Paper Guide for scientific research, and we highlight two international opportunities for clinicians to contribute to research on AI in healthcare.Research Opportunities:Clinicians – be part of the research into clinician use of AI, open globally LinkAI policy vs frontline reality survey (deadline 2 September) LinkResources:SPRIND Continuous Hormone Monitoring Challenge LinkIda Tin Coined Femtech. Now She's Funding Continuous Hormone Monitoring, Forbes LinkSensorFM: Towards a general intelligence and interface for wearable health data, Google Research LinkRecommendations:Paper Guide LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Brendan McAdams, a seasoned healthcare sales coach and expert, to break down what it really takes to succeed in healthcare tech and medical sales. Brendan shares practical advice for both new and experienced reps, including how to stop selling too early, listen more effectively, ask better questions, build trust with customers, and approach sales conversations as a consultant rather than simply trying to make a sale. They also discuss how clinicians can transition into healthcare tech sales, the importance of preparation and organization, strategies for accessing hard-to-reach accounts, and how sales professionals can develop the right mindset to stay motivated and continuously improve. If you want actionable strategies to become a more confident, effective, and customer-focused medical sales professional, this episode is a must-listen. Connect with Brendan McAdams: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

Episode 82 - Matthew Whitty, former NHS England Director of Innovation, Research and Life Sciences and now Director of Commercial Partnerships at MDClone, discusses NHS data strategy, safe AI adoption and protecting patient privacy.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

מה באמת קורה כשסטארטאפ נלהב פוגש את הבירוקרטיה והמורכבות של מערכת הבריאות? בפרק סיכום העונה השנייה של 'עושים חדשנות בבריאות', סיון ורדי מארחת את אורי גורן, מנהל מרכז החדשנות במרכז הרפואי מאיר מקבוצת כללית, לשיחה פתוחה על מה שבאמת עובד ובעיקר על מה שמכשיל מיזמים מבטיחים עוד לפני שהם יוצאים לדרך.אורי חושף את הדגלים האדומים שגורמים לסטארטאפים ליפול כבר בפגישה הראשונה, ומסביר למה הפיתוח הקלאסי של "עוד מסך לרופא" הוא טעות קריטית שמפספסת לחלוטין את העומס הקליני בשטח. בהמשך השניים דנים באתגרים המורכבים של פתרונות B2C המבוססים על אימוץ מטופלים, ובשאלה החשובה: איך AI יכול לשנות את המשחק ולעזור לנו להפוך ל"חולים טובים יותר" שמנהלים את הבריאות של עצמם בצורה חכמה. פרק חובה לכל יזם ויזמת בתחום ה-HealthTech שמחפשים תובנות פרקטיות וטיפים מעשיים שיחסכו לכם זמן יקר, כסף וטעויות קריטיות בדרך להצלחה בסקייל.

We're on summer break and replaying one of our favorite episodes. This episode originally aired on September 22, 2025.A wearable can collect endless data, but it only matters if people trust it enough to change their behavior.In this replay, Oura CEO Tom Hale joins Steve and Michael to explain how the company combines clinical-grade accuracy with a consumer-friendly product. They discuss why the ring's form factor makes overnight tracking so powerful, how Oura turns physiological signals into useful guidance, and why the company is being pulled faster than expected into traditional healthcare.We cover:Why sleep data can reveal changes in the body before symptoms appearHow Oura designed a health product that supports users without judging or nagging themWhy accuracy is the foundation for trust, predictions, and behavior changeHow Oura navigates the boundary between wellness products and regulated medical devicesThe company's expansion into Medicare Advantage, women's health, metabolic health, and clinical care—About our guest:Tom Hale is the Chief Executive Officer at ŌURA and a member of its board. As the CEO he sets the company's business strategy and vision to make health a daily practice for members all over the world. He has over 30 years of experience across the technology and consumer product industry.Before joining ŌURA, Hale was president of Momentive where he drove B2B strategy and led product growth. During his time there he was instrumental in taking the company public in 2018, leading the team in key acquisitions, and driving the evolution and rebranding of the company into a multiple SAAS business. Previously, he held leadership roles at HomeAway and Linden Lab as the Chief Operating Officer and Chief Product Officer, respectively, and held executive roles at Macromedia and Adobe.Hale has a Bachelor of Arts from Harvard University and sits on the boards of Cars.com, RocketReach, and NoiseAware.—If you're enjoying the show, we would so appreciate it if you left us a review!—

The Art of Making a Room Feel Human with Mike Mosquito and Maureen Nylin Have you ever wondered why the smaller, more intimate industry events on your calendar seem to generate more real business than the massive trade show floors? On this episode, part two of their series The Intimacy Shift, host Adam Turinas sits down with Mike Mosquito and Maureen Nylin, the duo behind the Buzz podcast, to find out exactly what happens once buyers are in the room. If you are planning your 2027 event strategy and trying to figure out where your budget should actually go, this conversation gives you the answer. Mike and Maureen have built their careers on being the people event organizers call when they want a room to feel less like a trade show and more like a reunion, and they pull back the curtain on how they do it. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Join Michelle Wiltse, Founder and CEO of CompanAIn, for a grounded discussion on why the tech industry's rush toward "AI-first" branding often undermines true enterprise value. In a market flooded with companies rushing to wrap basic wrapper interfaces around large language models, Michelle took a radically different path. Having previously led agentic AI capabilities and deployed multi-agent systems for major global institutions, she chose to apply this frontier technology where it matters most: eliminating health data fragmentation for companion animals nationwide. In this episode, Michelle shares why the smartest AI strategy prioritizes deliberate restraint—using AI only where it solves genuine structural problems—and how a mission-driven mindset beats superficial "AI theater" every time.

This week on Pulse: Amplify, healthcare's digital future won't be built by technology - it will be built by people.In this episode, Louise and George are joined by Jane Dwelly, Vice President International at CHIME and Chair of the Federation for Informatics Professionals (FedIP), to discuss why professional recognition, leadership and workforce capability are critical to healthcare's future, especially as healthcare enters the AI era.They explore the UK's landmark move to recognise digital health professionals, what other countries can learn, how AI is reshaping workforce skills, and whether the future could include internationally recognised standards for digital health professionals.Connect with Jane on LinkedInResources:FedIP, Federation for Informatics Professionals LinkCHIME CXO Summit, September @Cambridge LinkCHIME membership LinkProfessional Membership for the NHS Digital, Data and Technology Workforce – NHS LinkVisitPulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

This month is about the gap between what a system offers and what people actually get from it: drugs that work better with support nobody's paying for, AI that's already answering more medical questions than most doctors ever will, and a labor market where staying healthy can mean staying stuck. Halle and Michael break down the stories reshaping digital health in August.We cover:Why GLP-1 funding is shifting from prescribing platforms into "companion" ecosystemsThe FDA panel vote that opens a legal pathway for six unapproved peptides, and what this could meanOur thoughts on OpenAI's new ChatGPT Health product, now available to every US adultThe Florida pastor's lawsuit against OpenAIWhy nearly one in four US workers are staying in jobs they'd rather leave, just to keep their health insuranceThe healthcare argument buried inside the bill to make daylight saving time permanentLinks:Rock Health, H1 2026 digital health funding recapHalle's research piece, Virtual GLP-1 startups: Pill mills or the future of obesity care?RAPS, FDA advisory committee backs six peptides for compounding listTechCrunch, OpenAI makes ChatGPT Health available to all US usersCBS News, ChatGPT's medical advice nearly killed a Florida man, lawsuit claimsGallup, One in four US employees locked in jobs for health insuranceThe Hill, House passes Sunshine Protection Act—

In this episode of Medsider Radio, we sat down with David Veino, President and CEO of Neuros Medical.Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.  Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with David Veino, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:02) - David's 30-year medtech journey from cardiovascular devices to leading Neuros (04:38) - How Neuros is treating chronic post-amputation pain with on-demand neuromodulation (11:08) - Why Neuros completely changed its strategy halfway through the pivotal trial (15:36) - Why commercialization starts with referral pathways, not end-users (18:09) - How prosthetists became one of Neuros' most important referral sources (26:11) - What it takes to generate gold-standard clinical evidence for a first-of-its-kind therapy (37:41) - Building an investor pitch that earns the next meeting (41:42) - What gets David excited enough to invest in a medtech company

Curated Not Crowded – How to Win with Community-driven Events If you're a B2B healthcare marketer wondering whether your trade show budget is actually buying you anything real, this episode is for you. Host Adam Turinas sit down with Megan Antonelli, Founder and CEO of HealthIMPACT, to kick off a two-part series he's calling The Intimacy Shift, a look at why healthcare technology marketers are pulling money out of massive trade shows and putting it into smaller, curated, community-driven events instead. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Episode 81 - Paul Gallagher is an award-winning health journalist with 20+ years' experience covering major UK health stories. A former Health Correspondent at The i Paper, he's a regular commentator on LBC, Times Radio and the BBC.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Join Dr. Kal Patel, CEO and Co-Founder of BrightInsight, for an illuminating masterclass on navigating product-market fit (PMF) inside one of the most complex, highly regulated sectors in global business: healthcare. Every year, life science giants invest billions of dollars developing breakthrough biopharmaceutical therapies, yet nearly 50% of patients with chronic diseases drop off their prescribed medication regimes within the first twelve months. Drawing from his rare vantage point as a physician, former BCG strategist, former head of Amgen's Digital Health unit, and leader of BrightInsight, Dr. Patel breaks down why traditional "direct-to-consumer" wellness apps repeatedly fail, how to build enterprise software that biopharma giants trust to touch regulated therapies.

Every day, roughly 100 Americans die in crashes caused by human drivers. Yet when a self-driving car hesitates at an intersection or makes the news for an unusual mistake, public trust can evaporate.In this special episode, Dr. Jonathan Slotkin reads his latest Noema essay exploring why we demand perfection from machines while accepting human error as inevitable. Drawing on lessons from medicine, psychology, and autonomous vehicles, he argues that the biggest barrier to safer technology is trust.You'll learn:Why humans judge machine mistakes differently than human mistakesWhat healthcare learned about the difference between being safe and feeling safeWhy autonomous vehicles may already be far safer than human driversHow public perception can slow the adoption of life-saving technologyWhat every AI company should learn about transparency and trust —About our guest:Dr. Jonathan Slotkin is Chief Medical Officer for Strategy & Growth at Geisinger, where he drives growth at the intersection of care delivery, insurance, and digital transformation. A practicing neurosurgeon, he previously served as Geisinger's associate chief medical informatics officer.Jon's current research and writing examine safety, trust, and adoption of autonomous systems in public life. His New York Times guest essay on self-driving car safety was entered into the Congressional Record. His writing regularly appears in Harvard Business Review, STAT, and Noema Magazine. He has authored more than 70 peer-reviewed scientific publications.Previously, as co-founder and chief medical officer of Contigo Health, he partnered with the nation's largest employers to reimagine care for their associates. He co-founded Scrub Capital, a clinician-powered venture capital firm, where he serves as a Partner. He completed neurosurgery residency at The Brigham and Women's Hospital, Harvard Medical School, where he served as chief resident.—This piece was commissioned, edited, and published by Noema Magazine. Noema publishes longform journalism exploring fresh ideas. To read this piece and others, head to noemamag.com.—

In this episode of Medsider Radio, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Vijit Sabnis, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:17) - Vijit's path from Stanford, solar energy, and venture capital to building Adaptyx (07:25) - How Adaptyx is trying to do for hormones what continuous glucose monitors did for diabetes (13:50) - The signals Vijit looked for before founding Adaptyx (25:35) - How Adaptyx turned academic research into startup-speed learning cycles (32:15) - Why cortisol became the company's first clinical application (36:26) - How Adaptyx is designing new molecular data to fit existing clinical workflows (42:12) - Why new consumer health platforms opened new paths to commercialization (47:24) - Fundraising in an era of shorter attention spans

In the second of this two-part episode of French Insider, host Karl Buhler continues his conversation with Nicolas Nemeth, founder and CEO of Bonne et Filou, the French-inspired luxury "lifestyle" brand for dogs, and co-founder of Dumbo Health, a health tech startup focused on sleep apnea diagnosis and treatment. They discuss the mission behind Dumbo Health, the outdated state of sleep apnea diagnosis and treatment in the U.S., how the company is using AI to optimize a process that traditionally takes months into a matter of minutes, and what it means to build an "AI-native" company today.   What we discuss in this episode:   The mission behind Dumbo Health and the scale of the sleep apnea problem in the U.S. Why the current sleep apnea patient journey is slow, fragmented and difficult to navigate How Dumbo Health is digitizing diagnosis and treatment, from telehealth to at-home testing and device delivery Using AI and patient data to proactively coach patients and improve treatment adherence What it means to build an "AI-native" company versus simply integrating AI into existing workflows The shift from traditional software development to AI-driven, agent-based building processes How AI is reshaping investor priorities The cybersecurity risks that come with building fast in an AI-driven world The challenges of fundraising as a healthcare company in a market fixated on AI-agentic valuations   About Karl Buhler As an associate with the Corporate and Securities practice group and French Desk in Sheppard's New York office, Karl Buhler focuses on domestic and cross-border transactions, including mergers, acquisitions, joint ventures and complex commercial agreements in industries such as technology, communications, life sciences, energy, defense and aerospace. In particular, he advises foreign companies with the installation and development of their operations in the United States.   About Nicolas Nemeth Nicolas Nemeth is the co-founder of Dumbo Health, a digital sleep clinic that allows patients to skip the sleep lab and bring the entire obstructive sleep apnea journey home, and the Founder & CEO of Bonne et Filou, the first French-inspired luxury "lifestyle" brand for pets in the United States focused on delivering high-quality, luxury and innovative products in the pet industry. Nico began his career as an investment banker in LBO and M&A with 7 years of previous experience in New York City. He closed dozens of transactions worth a total of $5.0+ billion in secured financing, with a focus on Healthcare and Consumer deals. He is fluent in English and French with international experience gained in NYC, Boston, Paris and Melbourne. He has been living in New York City since 2011.   Contact Information Nicolas Nemeth  Karl Buhler  Additional Resources Dumbo Health Bonne et Filou Thank you for listening! Don't forget to SUBSCRIBE to the show to receive every new episode delivered straight to your podcast player every week. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Deezer, Amazon Music or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

How AI Aligned Marketing and Sales in Seven Months If you have ever felt like your marketing and sales teams are speaking two different languages, or that your best customer stories are locked away in someone's inbox instead of helping close deals, this episode is for you. Host Adam Turinas sat down with Jennifer Lazarz, Director of Marketing at Medical Informatics Corp, the company behind the SickBay Clinical Platform. In just seven months, Jennifer's team went from siloed content and frustrated salespeople to a three-pronged AI infrastructure that has fundamentally changed how marketing and sales work together. We get into the details of how she trained her team on generative AI tools, how she built consolidated document libraries in NotebookLM so salespeople stop chasing down information, and how she put FDA compliance guardrails in place so that everything the AI generates stays within the lines. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Have you ever wondered what truly drives someone to leap from curiosity about startups into the realm of angel investing—and what mindset shifts are crucial along the way? This episode of The Angel Next Door Podcast opens with that very question, as we explore the often untold personal and financial journeys that lie behind the checks investors write, and the ambitions founders chase. Our guest, Christa Downey, brings a unique lens as both an active angel investor and a leadership coach grounded in the vibrant startup ecosystem of Ithaca, New York. Christa Downey shares her path from engaging with the Cornell entrepreneurship community to backing mission-driven companies, investing alongside platforms like Chloe Capital and The Fourth Effect, and leveraging alternative vehicles such as self-directed IRAs to build wealth with purpose. Her commitment to fostering both financial returns and meaningful impact defines her approach and investments. In this conversation, Christa Downey dives into practical strategies for diversification, the pivotal role of money mindset for both founders and investors, and the often-overlooked emotional aspects of entrepreneurship—including navigating hard money conversations, founder agreements, and the difficult transition from founder to CEO. Listeners will gain concrete insights on angel investing, alternative wealth-building tools, and how intentional financial choices shape both companies and their leaders. This episode is a must-listen for anyone interested in reimagining their relationship with money, understanding the nuts and bolts of early-stage investing, and supporting the creation of a more inclusive, impactful startup culture.   To get the latest from Christa Downey, you can follow her below! https://www.linkedin.com/in/christabdowney/   Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing! Website: www.marciadawood.com Learn more about the documentary Show Her the Money: www.showherthemoneymovie.com And don't forget to follow us wherever you are! Apple Podcasts: https://pod.link/1586445642.apple Spotify: https://pod.link/1586445642.spotify LinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/ Instagram: https://www.instagram.com/theangelnextdoorpodcast/ TikTok: https://www.tiktok.com/@marciadawood

Healthcare companies are built to improve patients' lives. So why do so many prioritize shareholders over the people they're meant to serve?This week, Halle sits down with Eric Ries, author of Incorruptible, to unpack the rise of shareholder primacy, what it is, and why he believes it's at the root of many of society's biggest challenges. They discuss the surprising history of corporate governance, the lessons behind Novo Nordisk's century-long success, and what founders can do today to keep their companies aligned with their mission as they grow.We cover:Why shareholder primacy reshaped corporate America (and where we go from here)How Novo Nordisk's unusual ownership structure may have saved GLP-1 researchThe simple governance change that could preserve your company's mission for decadesHow boards, investors, and acquisitions can slowly pull companies away from their original purposeThe founder mistakes that make mission drift almost inevitableAbout our guest:Over the last two decades, Eric Ries's ideas about continuous innovation, long-term thinking, governance, and market reform have reshaped company building and management practices. He is the creator of the Lean Startup method, and the author of two New York Times bestsellers The Lean Startup and Incorruptible; The Leader's Guide; and The Startup Way. As a founder, he has put his own ideas into practice with The Long-Term Stock Exchange (LTSE); Answer.AI, an AI R&D lab; Virgil, a legal services startup; and IMVU. On The Eric Ries Show, he talks with world-class technologists, thought leaders, and executives building for the long-term. Check out his book, Incorruptible: Why Good Companies Go Bad…and How Great Companies Stay Great—

The State of Healthtech Marketing – Mid-Year Check-in Over the last month, host Adam Turinas has spoken with more than 30 health tech marketing leaders who are part of the Healthtech Marketing Network. He wanted to hear firsthand from them about how the first half of the year has gone and how they're feeling about the rest of 2026. He was surprised by what I heard. On this episode, he sits down with his colleague Mark Erwich, Chief Strategy Officer at Health Launchpad, to discuss what they learned. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

Episode 80 - Tom Whicher is CEO and Co-founder of DrDoctor. He co-founded the company after seeing patients struggle with hospital appointments and has since expanded it across NHS trusts, improving care and patient engagement.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Over the last decade, the number of drug candidates entering development has doubled, yet the number of successful drug approvals remains flat at ~50 per year.This week, we sit down with Formation Bio founder and CEO Ben Liu. His company has raised more than $600 million to build what he hopes will become the first new enduring pharmaceutical company in decades, powered by AI. Ben explains why he believes clinical development, not drug discovery, is becoming the industry's biggest bottleneck, and how AI could fundamentally change the economics of bringing new medicines to patients.We cover:Why there hasn't there been a big pharma company created since the 1980sWhich drug categories Ben believes could become the next GLP-1s and reshape healthcareWhy Formation Bio chose to become a pharmaceutical company instead of selling softwareThe real bottleneck in bringing medicines to patientsBen's roadmap for how AI will transform drug development over the next 10 to 20 yearsAbout our guest:Ben Liu is the co-founder and CEO of Formation Bio. He received his DPhil at Oxford as a Rhodes Scholar, leveraging machine-learning, AI, and big-data to develop diagnostics and therapeutics for Parkinson's and Alzheimer's disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start Formation Bio.Before Formation Bio, Ben graduated from Yale where he was awarded the college's highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow. Ben also serves as an Advisor to Harvard Business School's MS/MBA Program in Biotechnology.—

They built a $1.2 billion healthcare AI company in under three years, but they say the hardest part of healthcare AI isn't the AI.This week, Halle sits down with Assort Health co-founders and co-CEOs Jeffery Liu and Jon Wang, whose company reached a $1.2 billion valuation in under three years. They discuss why building great healthcare AI takes far more than good models, how they scaled from 15 employees to nearly 250 in a year, and what they've learned from more than 190 million patient interactions. They also share why voice AI is harder than it looks, how they're thinking about building durable moats in the age of foundation models, and why helping patients navigate the healthcare system may be one of AI's biggest opportunities.We cover:The AI role suddenly showing up at every healthcare startupThe surprising demographic that gives AI voice agents the highest satisfaction scoresHow healthcare AI is shifting from single-purpose tools to platforms that remember patients across every interactionWhy the biggest moat in healthcare AI may not be the model itselfThe biggest misconception investors have about moats in healthcare AIHow to triple your team without losing the culture that made the company successful—